Polynovo Ltd
PNV: XASX (AUS)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|#g%?g>j | LOCK|l< | LOCK|^gn>$p |
Polynovo: Solid Product Demand but Shares Appear Fairly Valued
Polynovo's first-half 2026 revenue of AUD 70 million rose 18% on the previous corresponding period, driven by a 25% increase in US sales to AUD 52 million. Sales of its new alternative product that has no sealing membrane, Novosorb MTX, were up 195% to AUD 6 million.
